Zhuang Tongtao, Wang Shenrong, Yu Xiaoqian, He Xiaoyun, Guo Hongbin, Ou Chunlin
Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Biomark Res. 2024 Aug 26;12(1):88. doi: 10.1186/s40364-024-00639-0.
Platelets are a significant component of the cell population in the tumour microenvironment (TME). Platelets influence other immune cells and perform cross-talk with tumour cells, playing an important role in tumour development. Extracellular vesicles (EVs) are small membrane vesicles released from the cells into the TME. They can transfer biological information, including proteins, nucleic acids, and metabolites, from secretory cells to target receptor cells. This process affects the progression of various human diseases, particularly cancer. In recent years, several studies have demonstrated that platelet-derived extracellular vesicles (PEVs) can help regulate the malignant biological behaviours of tumours, including malignant proliferation, resistance to cell death, invasion and metastasis, metabolic reprogramming, immunity, and angiogenesis. Consequently, PEVs have been identified as key regulators of tumour progression. Therefore, targeting PEVs is a potential strategy for tumour treatment. Furthermore, the extensive use of nanomaterials in medical research has indicated that engineered PEVs are ideal delivery systems for therapeutic drugs. Recent studies have demonstrated that PEV engineering technologies play a pivotal role in the treatment of tumours by combining photothermal therapy, immunotherapy, and chemotherapy. In addition, aberrant changes in PEVs are closely associated with the clinicopathological features of patients with tumours, which may serve as liquid biopsy markers for early diagnosis, monitoring disease progression, and the prognostic assessment of patients with tumours. A comprehensive investigation into the role and potential mechanisms of PEVs in tumourigenesis may provide novel diagnostic biomarkers and potential therapeutic strategies for treating human tumours.
血小板是肿瘤微环境（TME）中细胞群体的重要组成部分。血小板影响其他免疫细胞并与肿瘤细胞进行相互作用，在肿瘤发展中发挥重要作用。细胞外囊泡（EVs）是从细胞释放到TME中的小膜囊泡。它们可以将包括蛋白质、核酸和代谢物在内的生物信息从分泌细胞转移到靶受体细胞。这一过程影响各种人类疾病，尤其是癌症的进展。近年来，多项研究表明，血小板衍生的细胞外囊泡（PEVs）可以帮助调节肿瘤的恶性生物学行为，包括恶性增殖、抗细胞死亡、侵袭和转移、代谢重编程、免疫和血管生成。因此，PEVs已被确定为肿瘤进展的关键调节因子。因此，靶向PEVs是一种潜在的肿瘤治疗策略。此外，纳米材料在医学研究中的广泛应用表明，工程化的PEVs是治疗药物的理想递送系统。最近的研究表明，PEV工程技术通过结合光热疗法、免疫疗法和化疗在肿瘤治疗中发挥关键作用。此外，PEVs的异常变化与肿瘤患者的临床病理特征密切相关，这可能作为液体活检标志物用于早期诊断、监测疾病进展和肿瘤患者的预后评估。对PEVs在肿瘤发生中的作用和潜在机制进行全面研究，可能为治疗人类肿瘤提供新的诊断生物标志物和潜在的治疗策略。
